On the stock market since 2021, it operates in the world of health and science. It has 59 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $1.0B in the vault; even if every debt were paid off, $1.0B would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $96.2M against $0 in annual sales.
Over the last 12 months, executives reported 75 sells against just 20 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, TERN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TERN is a high-risk stock — not yet profitable, and its future rides on its product catching on.